Erectile Dysfunction Drug ZYDENA Captures No. 2 Position

ZYDENA, an erectile dysfunction treatment independently developed by Dong-A Pharmaceutical, became the second most prescribed drug of its kind in Korea last year. The industry and pharmaceutical market research agencies reported on February 25 that ZYDENA carved out a 24.8% market share by volume, nudging Lily Korea’ s CIALIS from the number two position. With 1,727,532 tablets sold last year, ZYDENA is quickly catching up to VIAGRA, of which 2,979,000 tablets were sold to account for 42.8% of the market. Third best-selling CIALIS represented 21.3% of the market in 2008, followed by Chong Kun Dang’s YAILA (4.3%), Bayer Healthcare’s LEVITRA (3.5%), and SK Chemical’s M-VIX (3.2%). It is notable that the three multinational products all slid in both sales volume and value, while sales of ZYDENA rose in both terms, by 22% and 19% respectively. ZYDENA made its debut in the global market as the fourth of its kind in December 2005. It overtook LEVITRA the next year as the third best-seller, and easily became the second best-seller in 2008, a mere three years after its launch. Last year, the erectile dysfunction treatment market totaled KRW78 billion, up only 0.4% from 2007. In the mean time, ZYDENA has so far won export agreements worth USD300 million in total, including USD 168 million with Brazil and 15 other South American countries, USD 50 million with Russia, and USD 23 million with Middle Eastern and North African countries. Dong-A Pharmaceutical , one of the Korea’s leading research-based pharmaceutical and healthcare companies, is committed to working for a better tomorrow by following its core value of integrity, excellence and respect for humanity. Dong-A Pharmaceutical has kept its No. 1 position in the Korean pharmaceutical market since 1967 with its Zydena(erectile dysfunction treatment), Stillen(gastritis treatment), Bacchus(refreshing tonic) and other 120 products. For further information, please visit www.donga-pharm.com Cautionary statement regarding forward-looking statements Dong-A Pharmaceutical cautions investors that any forward-looking statements or projections made by Dong-A Pharmaceutical, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. The forward-looking statements may include statements regarding product development, product potential or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Dong-A Pharmaceutical undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

The release as fetched from its publisher. donga-st.com ↗